Antisense Therapeutics Limited
ASX Code
ANP
Sector
Pharmaceuticals- Biotechnology & Life Sciences
Investor Centre
https://www.antisense.com.au/asx-announcements/
Website
https://www.antisense.com.au/
About
Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.
News
Research
| And a Door Opens Wide | |
| Potential Competitor on the Canvas | |
| FDA Feedback as Good As It Gets | |
| Paediatric Investigation Plan Almost Certain To Get the Tick and Other Notable Events | |
| Comprehensive Research Report | |
| Biopharmas Hit, but Buying Opportunities Created Antisense (ANP) & Kazia (KZA), Two Companies To Build Your Biopharma Portfolio Around | |
| Antisense Therapeutics (ANP) Taking a Quick Approach to Long COVID |